blood volume measurement News
-
Daxor corporation announces novel fluorescent tracer and phasetwo us air force contract award of $750,000 for point-of-care Optical blood volume analyzer
Daxor Corpora9on (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a phase-two contract from the United States Air Force (USAF) to implement a novel fluorescent tracer and op9cal sensing technology into a next-genera9on point-of-care blood volume analyzer. This is the fourth contract award Daxor has received from the Department of ...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing ...
-
New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...
-
Daxor Corporation Awarded Grant from the Center for Advancing Point of Care Technologies (Capcat) to Develop a Point-Of-Care Blood Volume Analyzer
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center (M2D2) funded by the National Heart, Lung, and Blood Institute and the National Center for Complementary and Integrative ...
-
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL. Mr. Feldschuh will present on May 25, 2022 at 4:30pm ET and will report on the many ...
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol ...
-
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will present at Maxim Group 2022 Virtual Growth Conference to be held March 28-30, 2022, 9:00 AM – 5:30 PM ET. The conference will feature a company presentation, fireside chats, roundtable discussions, and live Q&A with Mr. Feldschuh moderated ...
-
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart Association Scientific Sessions (AHA) at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022. “The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on ...
-
Daxor Announces Prospective Randomized Control Trial at Duke University Medical Center to Guide Volume Treatment in Heart Failure Patients
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a prospective randomized control trial (RTC) utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology to guide volume treatment in heart failure patients. Duke University ...
-
Daxor Awarded New Patent for Blood Volume Guidance Technology to Improve Treatment & Outcomes
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways. “We are very excited ...
-
Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the Annual Scientific Meeting of the Heart Failure Society of America (HFSA) which brings together the world’s leading experts in heart failure at the Gaylord National Harbor in Washington, DC from September 30th thru October 3rd, 2022. “We are excited to ...
-
New Data Shows 85% Reduction in One-Year Mortality for Medicare Heart Failure Patients With BVA-Guided Care
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from ...
-
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announced Launch Tennessee (LaunchTN) has awarded Daxor Corporation a SBIR/STTR matching fund grant for Daxor’s Phase II award from the Department of Defense in the amount of $200K for the development of its next-generation point-of-care blood volume analyzer. “Receiving this grant is a ...
-
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the prestigious Journal of Cardiac Failure demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF). The researchers showed that Daxor’s BVA-100 was able to measure intravascular volume overload in heart failure ...
-
Daxor Corporation Appoints Linda Cooper, Vice President Project Management
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. “Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team ...
-
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which brought together the world’s ...
-
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans ...
-
Daxor’s Blood Volume Analyzer (BVA-100) to Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled “An Observational Study of Neurologic Function after COVID-19 Infection” utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology. The study is ...
-
Newly Published Study Proves Value and CliNewly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluationnical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you